Patient
SITE015-0079
enrolled Phase IIIA Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · SITE015 (POL) (Dr. Ito)
consented 2025-12-01
Adverse events
5
Serious AEs
1
Open data queries
0
Luna dropout signal
—
not on Luna
Adverse events 5
Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-02-14 (study day 255); relationship: NOT RELATED
Grade 2 Alopecia — outcome: RECOVERED/RESOLVED; onset 2023-01-05 (study day 215); relationship: RELATED
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-12-13 (study day 192); relationship: RELATED
Grade 4 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2022-09-26 (study day 114); relationship: not assessed; serious criteria: life-threatening
Grade 2 Asthenia — outcome: RECOVERED/RESOLVED; onset 2022-09-09 (study day 97); relationship: RELATED
Data queries 0
No data queries
The CDM sweep raises queries on inconsistent fields.
Luna engagement
This participant doesn't use Luna
Invite them from the site to track mood, adherence and check-ins.